News

The new Boston Scientific offer represents a valuation of $80 per Guidant share, which would take the form of $42 cash and $38 in Boston Scientific stock. “We

This fall in profit is partly due to a 9% decrease in overall revenues from $832 million to $758 million. Sales in the quarter included $486 million for

This new candidate, a p38 kinase inhibitor, represents the second compound to advance to the clinic from the partnership between the companies. Under the terms of the collaboration

The peptides, TR-291144 and TR-290999, first synthesized at Trimeris, are distinct compounds derived from HR2 sequences of HIV. In connection with this event, Trimeris will receive a payment

The primary objective of the study is overall response rate, including patients with complete responses and partial responses. Secondary objectives of the study include, time-to-progression, duration-of-response and overall

Peramivir is an influenza neuraminidase inhibitor that, in preclinical studies, has shown potent, broad spectrum activity against multiple strains of flu, including the H5N1 virus. On December 22,

Alrx IM is derived from indomethacin, a non-steroidal anti-inflammatory drug (NSAID) normally administered in capsular form for the treatment of inflammatory diseases such as arthritis, muscle pain, and

The open-label, dose-escalation trial is designed to evaluate tolerability and pharmacokinetics of the drug following oral administration to patients with advanced cancer. In addition, the trial is designed

The collaboration includes an investigation of Acadia’s selective m1 agonists for treatment of schizophrenia and other neuropsychiatric disorders. Muscarinic receptors respond to the neurotransmitter acetylcholine and compounds that